Walvax Biotechnology Co., Ltd.

Multiple major Chinese vaccine manufacturers are expecting annual profits to have slumped in 2024, as fiercer competition, destocking at vaccination clinics and a slowing Chinese economy all weigh on

Almost as soon as COVID-19 vaccines became available, their recipients became either “Team Pfizer” or “Team Moderna,” while competing products from AstraZeneca PLC and Johnson & Johnson quickly fe

Pfizer Inc. is divesting most rights to its Prevenar 13 vaccine (13-valent, pneumococcal polysaccharide conjugate) in China to a domestic company, in the latest localization move involving vaccines f

Chinese developers of COVID-19 antivirals and vaccines are diverging on whether to stay in the game, underscored by mixed first-half progress against the mutating SARS-CoV-2 virus. The Omicron subvari